Prognostic Impact of AJCC Response Criteria for Neoadjuvant Chemotherapy in Stage II/III Breast Cancer Patients: Breast Cancer Subtype Analyses

The American Joint Committee on Cancer (AJCC) response criteria represent a simple and easily reproducible tool for response evaluation of patients on neoadjuvant therapy and a useful clinical prognostic marker for relapse-free survival (RFS). These criteria also have a prognostic impact in all four breast cancer subtypes, including luminal A in which pathologic complete response (pCR) has a limited role.

 BioMed Central Cancer